Since OSI-906 is a dual IGF1R/InsR inhibitor and both receptors are potential therapeutic targets in breast cancer [36] it is important to consider the inhibitory contribution of both receptors to OSI-906 effects. This evidence concerns the gene INSR and breast cancer.